Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Triaminic Softchews is a brand of over-the-counter (OTC) combination medications specifically designed for children, originally developed by Novartis. The product line features several formulations tailored to specific symptom clusters, including 'Allergy Sinus', 'Cold and Allergy', 'Chest Congestion', and 'Cough and Runny Nose'. These medications are delivered as chewable tablets ('softchews') to facilitate administration in pediatric populations. The active ingredients vary by formulation but generally include small molecules such as acetaminophen (analgesic/antipyretic), pseudoephedrine (nasal decongestant), chlorpheniramine (antihistamine), and guaifenesin (expectorant). These components work by targeting adrenergic receptors to constrict blood vessels in the nasal passages, blocking H1 receptors to reduce allergic responses, and inhibiting prostaglandin synthesis to alleviate pain and fever. Triaminic products are widely used to manage symptoms of the common cold, influenza, and seasonal allergies.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Triaminic Softchews.